Preferred Label : pan-RAF Inhibitor QLH11906;
NCIt definition : An orally bioavailable inhibitor of all members of the serine/threonine protein kinase
Raf family, including A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic
activity. Upon oral administration, pan-RAF kinase inhibitor QLH11906 binds to and
inhibits the activity of Raf, including B-Raf mutated forms such as the B-Raf V600E
mutation. This prevents the activation of Raf-mediated signal transduction pathways,
which may inhibit tumor cell growth. Raf protein kinases play a key role in the RAF/mitogen-activated
protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling
pathway, which is often dysregulated in human cancers and plays a key role in tumor
cell proliferation and survival. The valine to glutamic acid substitution at residue
600 accounts for the majority of BRAF gene mutations. The oncogenic product, BRAF(V600E)
kinase, exhibits elevated activity that over-activates the MAPK signaling pathway.;
Molecule name : QLH 11906; QLH-11906;
NCI Metathesaurus CUI : CL1798796;
Origin ID : C190136;
UMLS CUI : C5783516;
Semantic type(s)
- concept_is_in_subset
- has_target
